Sir,
Sorsby fundus dystrophy is a rare retinal dystrophy of autosomal-dominant inheritance characterized by central vision loss before the fifth decade of life, secondary to choroidal neovascularization (CNV) and/or pigment epithelium atrophy. The natural history of the condition involves early development of lesion fibrosis.1 The genetic background of the disease resides in a mutation in the tissue inhibitor of metalloproteinase 3 (TIMP3) gene.2 We report here a case of Sorsby fundus dystrophy successfully treated with repeated injections of ranibizumab.
Case report
The 41-year-old patient presented in January 2007 with sudden onset distortion of vision in his left eye. Visual acuity was 6/5 OD and 6/18 OS on Snellen chart. Fluorescein angiography revealed OS occult CNV. No treatment was administered, and in October 2007, an extensive macular hemorrhage developed with vision dropping to 6/60. Despite a single session of verteporphin photodynamic treatment in November 2007, the lesion relentlessly progressed to a disciform scar. In April 2009, the patient developed distortion in his right eye with 6/36 vision. A classic subfoveal CNV was identified. DNA analysis revealed the presence of mutation c.610A>T (p.Ser204Cys) in exon 5 of the TIMP3 gene and confirmed the diagnosis of Sorsby fundus dystrophy. After his first intravitreal injection of ranibizumab to the right eye in May 2009 (Figure 1a), vision improved to 6/15. He received 14 injections of ranibizumab for persistent intraretinal fluid identified on optical coherence tomography until February 2011, at which point disease quiescence was established (Figures 1b and 2). Visual acuity stabilized at 6/15 without disease reactivation 6 months thereafter (Figure 1c).
Comment
Therapeutic management of CNV in Sorsby fundus dystrophy remains challenging. Treatment options reported on a limited number of case series include argon laser photocoagulation, PDT alone or in combination with intravitreal triamcinolone and intravitreal bevacizumab.1 Aggressive recurrence has been reported for extrafoveal CNV treated with argon laser,3 while PDT treatment for subfoveal CNV was ineffective.4 Few reports of the use of intravitreal1 or systemic5 bevacizumab have claimed moderate benefit. To our knowledge, this is the first report of the use of ranibizumab in Sorsby fundus dystrophy, with excellent response and long-standing favorable visual outcome. We also would like to draw attention to the extra benefit of effective treatment for CNV in Sorsby fundus dystrophy, in terms of more time spent in active employment, as this condition predominantly affects patients in the productive age range.
References
Sivaprasad S, Webster A, Egan C, Bird A, Tufail A . Clinical course and treatment outcomes of Sorsby fundus dystrophy. Am J Ophthalmol 2008; 146: 228–234.
Weber BH, Vogt G, Pruett RC, Stohr H, Felbor U . Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby’s fundus dystrophy. Nat Genet 1994; 8: 352–356.
Holz FG, Haimovici R, Wagner DG, Bird AC . Recurrent choroidal neovascularization after laser photocoagulation in Sorsby’s fundus dystrophy. Retina 1994; 14: 329–334.
Peiretti E, Klancnik JM, Spaide RF, Yannuzzi L . Choroidal neovascularization in Sorsby fundus dystrophy treated with photodynamic therapy and intravitreal triamcinolone acetonide. Retina 2005; 25: 377–379.
Prager F, Michels S, Geitzenauer W, Schmidt-Erfurth U . Choroidal neovascularization secondary to Sorsby fundus dystrophy treated with systemic bevacizumab (Avastin). Acta Ophthalmol Scand 2007; 85 (8): 904–906.
Acknowledgements
This work was supported by the NIHR Manchester Biomedical Research Centre.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Balaskas, K., Hovan, M., Mahmood, S. et al. Ranibizumab for the management of Sorsby fundus dystrophy. Eye 27, 101–102 (2013). https://doi.org/10.1038/eye.2012.221
Published:
Issue Date:
DOI: https://doi.org/10.1038/eye.2012.221